Wells Fargo & Company Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $900.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target trimmed by Wells Fargo & Company from $1,050.00 to $900.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Barclays lowered their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Citigroup initiated coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a “neutral” rating and a $895.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,037.33.

Regeneron Pharmaceuticals Stock Down 5.0 %

Shares of Regeneron Pharmaceuticals stock opened at $696.88 on Friday. The business has a fifty day simple moving average of $751.44 and a 200 day simple moving average of $961.06. The stock has a market cap of $76.58 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $691.00 and a 12 month high of $1,211.20.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Mizuho Securities USA LLC boosted its stake in shares of Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Tri Locum Partners LP boosted its position in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after buying an additional 8,949 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares in the last quarter. Finally, Catalytic Wealth RIA LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $1,334,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.